CLX

Business profile & competitive position

The Clorox Company is a Consumer Defensive name in the Household & Personal Products industry. It is a multinational manufacturer and marketer of consumer and professional products, reporting fiscal 2026 net sales of $6.7 billion with roughly 9,200 employees operating in approximately 25 countries and selling into about 95 markets. Its consumer-facing portfolio spans Clorox, Pine-Sol, Glad, Fresh Step, Kingsford, Hidden Valley, Brita, and Burt’s Bees, while its professional arm distributes under Purell, CloroxPro, and Clorox Healthcare.

The company’s 8.7% net margin is positive and consistent with a packaged-goods manufacturer that can extract some value from brands, but it does not point to outsized pricing power. The far more eye-catching figure is ROE of -1893.5%. A negative reading that extreme typically signals a thin or negative equity base—often driven by debt, share repurchases, or accounting adjustments—rather than an operational loss on every dollar of equity. That means Return on Equity, by itself, is not a clean read on competitive moat here. A more useful lens is customer concentration: Walmart accounted for 26% of fiscal 2026 net sales, and the five largest customers represented about half of consolidated net sales. That structure implies scale, shelf access, and brand equity matter, but it also means a meaningful slice of bargaining power sits with a handful of retailers.

A real strategic move in this direction is the April 2026 completion of the GOJO Industries acquisition, which added Purell-led health and hygiene assets and expanded Clorox’s business-to-business exposure. That diversification matters for the competitive map because it moves Clorox deeper into professional and institutional channels, where purchase decisions are stickier and less dependent on any single retailer’s shelf space.

Financial posture

At a recent price of $81.40, Clorox carries a $9.8 billion market capitalization and trades at a P/E of 16.9. The net margin is 8.7%, and beta sits at 0.54, which is consistent with a low-volatility consumer staples stock.

Valuation at 16.9x earnings is relatively modest by historical staples standards, but it does not automatically signal value. ROE of -1893.5% distorts the usual profitability picture; when equity is deeply negative, P/E becomes the more functional earnings yardstick, and in that respect the stock trades closer to defensive-market norms. The low beta suggests the equity is less sensitive than the broad market to cyclical swings, which is what one expects from a household-products company. The key tension in the financial posture is reliable consumer demand versus the balance-sheet mechanics that produce an abnormally negative ROE.

Strategic priorities & outlook

Clorox’s most recent 10-K frames a company in transition. The headline framework is the IGNITE strategy, built around four stated choices: fuel long-term profitable growth, innovate consumer experiences, reimagine how the company and its people work, and continuously evolve the product portfolio.

Operationally, management is in the middle of a new enterprise resource planning (ERP) system rollout and a broader digital transformation designed to create long-term efficiencies across the supply chain, digital commerce, innovation, and brand building. That transition has measurable consequences: fiscal 2026 organic sales and earnings declined, and diluted EPS fell 26%, partly because ERP transition timing had pulled some sales forward into fiscal 2025.

Besides the ERP work, the company plans to invest in strong brands and strategic digital capabilities through a simplified operating model, while advancing health and hygiene expansion and portfolio optimization. The integration of GOJO sits inside that priority set, as does growing professional and institutional markets. Another concrete recent event is the January 31, 2026 expiration of the Glad bags and wraps venture with Procter & Gamble, after which Clorox purchased P&G’s 20% interest and retained core intellectual property licenses on a royalty-free basis.

Macro & geopolitical exposure

As a Household & Personal Products business, Clorox is exposed to the predictable macro forces that shape the packaged-goods supply chain. Input-cost volatility is the most direct: resins, chemicals, pulp, packaging, and freight can move with energy prices, currency markets, and trade policy. Any broad-based tariffs on raw materials or finished goods could pressure margins, while a stronger U.S. dollar would compress translated earnings from approximately 25 countries where Clorox operates.

Regulatory exposure is structural as well. Disinfectants, cleaning chemicals, and personal-care products are overseen by agencies such as the EPA and FDA in the U.S., with comparable bodies abroad, so labeling, safety, and efficacy rules are an ongoing compliance cost and a potential source of disruption. On the demand side, the category is defensive—household cleaning, trash bags, cat litter, and salad dressing are not discretionary—but consumers still trade down to private labels or smaller pack sizes when inflation lingers. Retail concentration adds another layer: because Walmart alone represented 26% of fiscal 2026 net sales, pricing negotiations, shelf resets, and inventory destocking by a single large customer can create outsized quarterly noise.

Recent developments

News flow around the stock has been busy on September 28, 2026. PR Newswire reported that Clorox announced the official launch of Clorox Purell ProCare™, a clear tie-in to the GOJO acquisition and the professional health-and-hygiene expansion the 10-K emphasizes. On the same day, dividend-focused coverage from 247WallSt.com noted that Clorox raised its dividend again and asked whether earnings can keep up, while Seeking Alpha published a piece titled “Clorox: The 6% Yield & Bargain Valuation Can’t Fix A Slow Recovery.” Earlier that week, on September 24, 2026, Seeking Alpha also carried “Clorox’s Selloff May Not Be Over Yet (Rating Downgrade).” Collectively, the headlines point to a stock where the dividend yield and valuation are attracting attention, but sell-side and commentary sentiment is focused on whether the operational recovery can match those headline attractions.

Earnings behavior & post-earnings drift

Over the last eight reported quarters, Clorox has beaten earnings estimates six times for a beat rate of 75%, with an average earnings surprise of 9.6%. The average 5-day price move in the five trading days after those reports is +1.67%, classified as an “up” drift.

The most recent quarters show the relationship between beats and price reaction is not one-for-one. On August 3, 2026, Clorox reported actual EPS of $1.66 versus an estimate of $1.64, a 1.2% beat, yet the stock rose 6.52% the next day and 9.61% over the following five days. The prior quarter, April 30, 2026, produced a stronger 5.8% beat ($1.64 actual vs. $1.55 estimate) but the stock sold off 9.67% the next day and finished the next five days down 4.49%. That divergence between the magnitude of the beat and the direction of the post-earnings move suggests the market is reacting as much to guidance, commentary, and prior positioning as to the headline number.

The February 3, 2026 report was a miss: actual EPS came in at $1.39 versus an estimate of $1.43, a -2.8% surprise, but the stock still climbed 2.43% the next day and 5.63% over the next five days. Before that, on November 3, 2025, Clorox beat by 3.9% ($0.85 actual vs. $0.818 estimate), yet drifted -4.08% over the following five days. The next report is scheduled for November 3, 2026 after the close, with a consensus EPS estimate of $1.11. Given the unofficial consensus, the stock’s post-earnings path will likely depend on whether management can frame the ERP transition and GOJO integration as sources of future operating leverage rather than ongoing headwinds.